Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany

Bio-Techne Corporation announced that its shareholders have voted to approve the definitive agreement for the acquisition of the company by Merck KGaA, Darmstadt, Germany, at a Special Meeting of Shareholders held today.

Kim Kelderman, President and Chief Executive Officer of Bio-Techne, expressed gratitude to the shareholders for their support, calling it a significant milestone in the transaction process. Kelderman stated that the merger will unite their complementary life sciences organizations, providing substantial cash value to Bio-Techne shareholders and enhancing customer support across life science workflows.

The company confirmed that the final voting results will be certified by an independent inspector of elections and reported in a Form 8-K with the U.S. Securities and Exchange Commission. Additionally, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act related to the transaction expired on September 18, 2026. Bio-Techne anticipates closing the transaction by late 2026 or early 2027, pending customary closing conditions and regulatory approvals.

Bio-Techne, headquartered in Minnesota, has been in operation for 50 years, providing reagents, analytical instruments, and diagnostic products. The company recorded over $1.2 billion in net sales in fiscal year 2025 and employs more than 3,000 people globally.